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ABSTRACT
There is increasing interest in the use of non-toxic natural products for the 
treatment of various pathologies, including cancer. In particular, biologically active 
constituents of the ginger oleoresin (Zingiber officinale Roscoe) have been shown to 
mediate anti-tumour activity and to contribute to the anti-inflammatory, antioxidant, 
antimicrobial, and antiemetic properties of ginger. Here we report on the inhibitory 
properties of [10]-gingerol against metastatic triple negative breast cancer (TNBC) 
in vitro and in vivo. We show that [10]-gingerol concentration-dependently induces 
apoptotic death in mouse and human TNBC cell lines in vitro. In addition, [10]-gingerol 
is well tolerated in vivo, induces a marked increase in caspase-3 activation and inhibits 
orthotopic tumour growth in a syngeneic mouse model of spontaneous breast cancer 
metastasis. Importantly, using both spontaneous and experimental metastasis 
assays, we show for the first time that [10]-gingerol significantly inhibits metastasis 
to multiple organs including lung, bone and brain. Remarkably, inhibition of brain 
metastasis was observed even when treatment was initiated after surgical removal 
of the primary tumour. Taken together, these results indicate that [10]-gingerol may 
be a safe and useful complementary therapy for the treatment of metastatic breast 
cancer and warrant further investigation of its efficacy, either alone or in combination 
with standard systemic therapies, in pre-clinical models of metastatic breast cancer 
and in patients.
                                                               Research Paper
Oncotarget72261www.impactjournals.com/oncotarget
INTRODUCTION
Breast cancer is the third most diagnosed cancer 
worldwide and the second highest cause of death among 
women in developing countries [1]. TNBC that accounts 
for 10–20% of cases is characterised by rapid progression 
to metastasis [2–4]. Patients with TNBC do not respond to 
endocrine or HER2-targeted therapies due to the lack of 
oestrogen, progesterone or HER2 receptor expression [5]. 
Whilst initially responsive to chemotherapy, relapse 
is common, with the emergence of chemo-resistant 
metastases inevitably resulting in death [6]. Up to 30% 
of advanced TNBC patients develop incurable brain 
metastases for which chemotherapy provides little benefit, 
in part due to poor ability of most chemotherapeutic 
agents to cross the blood-brain barrier [7, 8]. Thus, the 
limited long-term efficacy of chemotherapy in advanced 
TNBC patients and its normal tissue toxicity remain 
primary concerns [9, 10], motivating the search for natural 
products with fewer side-effects as an alternative or 
complementary chemotherapy for metastatic breast cancer 
and other malignancies [11–13].
Gingerols, the major pungent constituents in the 
ginger (Zingiber officinale Roscoe) oleoresin from fresh 
rhizome, comprise a series of homologues differentiated 
by the length of their alkyl chains, with [6]-gingerol being 
the most abundant [14]. Increasing evidence indicates that 
gingerols, especially [6]-gingerol, mediate anti-tumour 
and anti-metastatic activity in vitro and in vivo against 
a variety of tumour types, including breast cancer [15]. 
Fewer studies have investigated the anti-tumour properties 
of [10]-gingerol and relatively little is known about its 
mechanism of action. In colon cancer cells, [10]-gingerol 
induces cell cycle arrest, elevation of intracellular Ca2+ 
and caspase-dependent apoptosis [16, 17]. More recently, 
Joo and colleagues [18] reported that inhibition of MDA-
MB-231 breast cancer cell proliferation and invasion by 
[10]-gingerol is associated with inactivation of AKT and 
p38MAPK. However, to our knowledge, its anti-tumour 
activity in vivo has not been investigated, most likely 
due to its lower abundance and difficulty of purifying 
sufficient biologically active [10]-gingerol.
Previously, we reported a new methodology for 
efficient isolation and purification of [10]-gingerol 
by reverse-phase HPLC [19]. Our study showed that 
[10]-gingerol is a more potent inhibitor than [6]- or 
[8]-gingerol, with selectivity towards breast cancer cells 
compared to normal fibroblasts in vitro. In addition, more 
recently we have demonstrated that [10]-gingerol is able 
to revert the malignant phenotype of breast cancer cells in 
three-dimensional culture [20]. Interestingly, [10]-gingerol 
also mediates potent anti-neuroinflammatory activity 
[21], an important manifestation likely to contribute to 
the development of brain metastases [22]. Therefore, 
[10]-gingerol could potentially benefit breast cancer 
patients with brain metastasis through its direct anti-tumour 
and/or neuro-protective properties. Here, we show that 
[10]-gingerol induces apoptosis in aggressive mouse and 
human TNBC cells. Importantly, using a clinically relevant 
syngeneic model of breast cancer brain metastasis, we 
demonstrate for the first time that [10]-gingerol inhibits 
tumour growth and spontaneous metastasis to multiple 
organs, including lung, bone and brain.
RESULTS 
[10]-gingerol induces apoptosis of metastatic 
TNBC cells 
The activity of [10]-gingerol against brain 
metastatic cells that are typically more resistant to therapy 
has not been reported. We initially compared the effect of 
[10]-gingerol on mouse (4T1Br4) and human (MDA-MB-
231BrM) brain metastatic tumour variants versus isogenic 
lines that are highly metastatic to lung and/or bone but not 
to brain (4T1BM2 and MDA-MB-231).
[10]-gingerol inhibited the proliferation of all 
cell lines tested (Figure 1A). However, brain-metastatic 
variants were less sensitive than non-brain metastatic 
lines, as evidenced by their higher IC50 values (Figure 1A). 
Treatment with [10]-gingerol for 24 h caused significant 
cell death and detachment of confluent 4T1Br4 or MDA-
MB-231BrM cultures at high concentration (100 µM), 
whereas [10]-gingerol had a partial effect on cell viability 
and attachment at 50 µM and only negligible effect 
at low concentration (10 µM) (Figure 1B). Similarly, 
[10]-gingerol concentration-dependently inhibited colony 
formation at low cell density, with partial inhibition at 
10 µM and 50 µM and almost complete inhibition at 
100 µM (Figure 1C). Consistent with a cytotoxic activity 
rather than an anti-proliferative activity of [10]-gingerol, 
cell cycle analyses in either cell line revealed only 
marginal changes in the proportion of cells in G0/G1, S 
phase or G2/M phase but accumulation of cells in sub-G1 
after 24 h treatment with 50 µM [10]-gingerol (Figure 1D). 
Attempts to measure cell cycle phases after 24h treatment 
with 100 µM [10]-gingerol gave inconsistent results 
due to the extensive cell death and loss of DNA during 
processing of both cell lines (data not shown).
To confirm that [10]-gingerol induces apoptosis, 
4T1Br4 cells were treated with 10 µM, 50 µM or 
100 µM [10]-gingerol for 8h, stained for PE-Annexin-V 
and analysed by flow cytometry. [10]-gingerol induced 
a concentration-dependent increase in early and late 
apoptotic cells (Figure 2A). This was confirmed by 
TUNEL staining showing approximately 40% apoptosis 
after treatment with [10]-gingerol (50 µM) for 18 h 
(Figure 2B). Similar observations were made in MDA-
MB-231BrM cells (Supplementary Figure 1). Early 
induction of caspase activation was analysed by 
western blotting on cell lysates from control and 50 µM 
[10]-gingerol-treated cells for 6 h (Figure 2C). We found 
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Figure 1: [10]-gingerol induces concentration-dependent cell death in mouse and human metastatic TNBC cells 
in vitro. (A) Differential sensitivity of mouse and human metastatic TNBC cells to [10]-gingerol. Cells were treated with increasing 
concentrations of [10]-gingerol and proliferation measured after 3 days using the SRB colorimetric assay. Data show mean ± SD of 6 
replicates/dose from a representative experiment (n = 3). IC50 values for each cell line are indicated in the bottom panel. (B) [10]-gingerol 
induces morphological changes and cell detachment in vitro. Confluent monolayers of 4T1Br4 and MDA-MB-231BrM were treated with 
the indicated concentrations of [10]-gingerol and changes in cell morphology and adherence were visualised after 24h on an inverted 
microscope. Note the significant loss of membrane integrity (50 µM) and reduced number adherent cells with 100 µM [10]-gingerol 
treatment. Scale bar, 50 µm. (C) Effects of [10]-gingerol on colony formation at low cell density. 4T1Br4 (100 cells/well) and MDA-MB-
231BrM cells (300 cells/well) were seeded in 6-well plates, allowed to adhere overnight at 37°C and treated with indicated concentrations 
of [10]-gingerol or vehicle (DMSO) alone for 24 h. Colonies (> 50 cells) formed after 8 days were stained with a solution of crystal violet, 
photographed and counted. Data show representative wells at each [10]-gingerol concentration (left panel). Assays were repeated three 
times in triplicates and data show mean ± SD of triplicates from a representative experiment (right panel). **p < 0.01, ***p < 0.001, 1-way 
ANOVA, Bonferroni post-test. (D) Effect of [10]-gingerol on cell cycle. Adherent 4T1Br4 (top panels) and MDA-MB-231Br cells (bottom 
panels) were treated for 24h with indicated concentrations of [10]-gingerol, processed for cell cycle analysis and DNA content analysed 
by flow cytometry as described in Materials and methods. Data show mean % of cells in each cycle phase ± SD from 3 experiments 
and statistical difference between treatment groups for each phase of the cell cycle analysed by 2-way ANOVA and Tukey’s multiple 
comparison test. *p < 0.05, **p < 0.01, ***p < 0.001.
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that [10]-gingerol induced potent activation of caspase-3 
and caspase-9 in both cell lines under these conditions. 
In contrast, only low levels of caspase-8 were detected 
and did not change significantly between control and 
[10]-gingerol-treated cells.
[10]-gingerol inhibits 4T1Br4 orthotopic tumour 
growth and spontaneous metastasis
We validated the anti-tumour effects of 
[10]-gingerol in vivo using metastatic 4T1Br4 tumours. 
[10]-gingerol (5 mg/Kg) was administered daily from 
day-9 to day-23 and the mice sacrificed on day-26. At 
this dose, [10]-gingerol was well tolerated, with no 
significant bodyweight loss  (Supplementary Figure 2A). 
Gross histological examination of livers and kidneys 
and H&E staining revealed no evident toxicity 
(Supplementary Figure 2B). Importantly, tumour growth 
was partially inhibited, with inhibition being most evident 
between days 19–23 (Figure 3A). Treatment was stopped 
on day 23 when control mice began showing early signs of 
ill-health due to metastatic disease and the experiment was 
terminated when control mice showed clear signs of high 
metastatic burden. As expected, tumour growth resumed 
upon cessation of [10]-gingerol treatment and tumour 
weight was not significantly different at endpoint (day 26) 
(Figure 3B). However, IHC staining of cleaved (active) 
caspase-3 in primary tumours showed a dramatic increase 
Figure 2: [10]-gingerol induces concentration-dependent apoptosis in metastatic TNBC cells in vitro. (A) Flow cytometric 
analysis of Annexin-V in [10]-gingerol-treated 4T1Br4 cells. 4T1Br4 cells were treated with 0, 10, 50 and 100 µM [10]-gingerol for 8 h, 
fixed and stained with PE-Annexin-V and 7-AAD as described in Supplementary methods. Annexin-V positive cells are indicated with a 
red circle and the percentage of early and late apoptotic cells are indicated in the lower and upper right quadrants respectively. (B) TUNEL 
positivity was determined after 18h treatment with 10 or 50 µM of [10]-gingerol as indicated and as described in Supplementary methods. 
Representative images are shown on the left. Scale bar = 100 µm. The number of positive cells were counted and the data expressed as 
mean % of positive cells ± SD from six 10× images/condition (right panel). Statistical significance was determined using a 1-way ANOVA, 
Bonferroni post-test, **p < 0.01, ***p < 0.001. (C) Caspase expression following [10]-gingerol treatment in vitro. Expression of pro- and 
activated caspases in 4T1Br4 and MDA-MB-231BrM cells was analysed by western blotting after 6 h exposure to [10]-gingerol (50 µM) 
as described in Materials and Methods. α-tubulin or β-actin was used as loading control as indicated.
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in the number of apoptotic cells in [10]-gingerol-treated 
mice (Figure 3C). Moreover, immunostaining of the 
proliferation marker Ki67 in primary tumours did not show 
a significant difference between control and [10]-gingerol-
treated mice (Figure 3D). Metastatic burden in lung was 
significantly decreased by [10]-gingerol (Figure 3E, 3F), 
with a trend towards reduced bone metastasis as well (data 
not shown).
[10]-gingerol used at 5 mg/kg partially reduced 
bone metastasis but was not sufficient to achieve statistical 
significance. We reasoned that a higher dose may be 
required to efficiently target metastatic disease. Thus, 
for subsequent experiments, [10]-gingerol was used at 
10 mg/kg. Bone metastasis was further analysed in an 
experimental metastasis assay in which the formation of a 
primary tumour is bypassed by direct injection of 4T1Br4 
cells into the left cardiac ventricle (Figure 4). [10]-gingerol 
(10 mg/Kg) was administered one day after tumour cell 
inoculation and continued daily until completion on 
day 12. Under these conditions, femoral metastases were 
significantly inhibited (Figure 4A). While spine analysis 
showed a trend toward decreased metastasis (Figure 4B), 
combined metastatic burden scores for femurs + spine 
from same mice were significantly lower in [10]-gingerol-
treated animals (Figure 4C).
To further evaluate the clinical relevance of our 
findings and to test the impact of [10]-gingerol (10 mg/kg) 
on the development of late brain metastases, we 
completed an experiment where treatment commenced 
one day after surgical removal of the primary tumour at 
~0.5 cm3 (~0.5 g) and continued for 14-days (Figure 5A). 
Interestingly, body weight measurement over the 
subsequent 14 days of treatment showed that control mice 
lost weight, indicative of cachexia typically observed 
in mice with a high tumour burden and commonly 
observed in advanced patients. In contrast, mice from 
the [10]-gingerol group gained some weight (Figure 5B). 
Daily monitoring of animals also indicated a healthier 
general appearance in the [10]-gingerol group, as 
evidenced by the level of activity and coat appearance 
compared to controls. Consistent with these observations, 
mCherry fluorescence imaging of brains at endpoint 
indicated a significantly lower incidence of mice with 
brain lesions in the [10]-gingerol-treated group (1/13) 
compared to controls (7/13) (Figure 5C, 5D). Moreover, 
[10]-gingerol reduced spontaneous lung and bone 
metastatic burden (Figure 5E–5H).
Histological examination of brain lesions from 
either control mice or mice treated with [10]-gingerol 
(10 mg/kg) by H&E and IHC staining of GFAP, revealed 
highly vascularised lesions and recruitment of GFAP+ve 
activated astrocytes in the periphery of metastatic lesions, 
indicative of reactive glia (Supplementary Figure 3A). 
Surprisingly, we did not detect activated/cleaved caspase-3 
in brain lesions from either control or [10]-gingerol-
treated mice indicating that once established, brain 
metastases may become refractory to [10]-gingerol 
inhibition (Supplementary Figure 3B). Collectively, the 
results indicate that [10]-gingerol promotes apoptotic 
death, inhibits TNBC growth and metastasis to multiple 
organs in vivo.
DISCUSSION
We investigated the anti-tumour/metastatic 
properties of [10]-gingerol against brain metastatic 
TNBC in vitro and in vivo. Our data demonstrate for the 
first time that [10]-gingerol inhibits TNBC orthotopic 
growth and spontaneous metastasis to multiple organs. 
Although [10]-gingerol only had a modest effect of 
primary tumour volume in vivo, histological examination 
showed more extensive cell death within mammary 
tumours of [10]-gingerol-treated mice. Further, we found 
that [10]-gingerol promotes cell death primarily via 
induction of caspase-dependent apoptosis, evidenced by 
a significant increase in caspase-3 activation throughout 
primary tumours, cleavage of caspase-3 and -9 in vitro, 
or accumulation of cells in sub-G1, TUNEL positivity 
and concentration-dependent increase in annexin-V 
staining in vitro. These observations are consistent with 
those made in cervical cancer cells [23] and colon cancer 
cells [17] in which [10]-gingerol predominantly induced 
time-dependent accumulation of cells in sub-G1 at similar 
concentrations (30–50 µM) to the IC50 values we have 
observed in TNBC cell lines. Moreover, in agreement with 
our results, Ryu and Chung [17] found that induction of 
cell death was associated with cleavage of caspase-3 and 
-9, indicating that [10]-gingerol induces apoptosis via the 
intrinsic pathway.
Interestingly, recent studies have reported that 
[10]-gingerol inhibits cell growth through its effect 
on both, cell cycle progression and survival in breast 
cancer cells, although the results from these studies are 
conflicting. One study showed that 10 µM [10]-gingerol 
was sufficient to partially prevent serum-induced 
MDA-MB-231 cell cycling [18]. Others reported that 
[10]-gingerol inhibits TNBC cell growth (including 
4T1 and MDA-MB-231 cells) in vitro at concentrations 
≥ 50 µM [24]. Surprisingly, the authors reported that 
MDA-MB-231 cells accumulate in S-phase but this 
effect required treatment for 72 h with concentrations 
of [10]-gingerol as high as 200 µM, a concentration we 
found to potently and rapidly induce apoptotic death in 
4T1Br4 and MDA-MB-231BrM brain-metastatic variants. 
Moreover, Bernard and colleagues [24] found that 
[10]-gingerol-induced cell death was not inhibited by the 
broad spectrum caspase inhibitor zVAD-fmk, suggesting 
an additional caspase-independent mechanism. The 
reasons for the discrepancies between these studies and 
ours are unclear but could be in part due to differences 
in sensitivity to [10]-gingerol between brain-metastatic 
variants and other TNBC lines or to the methodology and 
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Figure 3: [10]-gingerol delays orthotopic tumour growth and inhibits spontaneous metastasis. (A) Tumour growth rate. 
4T1Br4 cells (1 × 105) were inoculated into the mammary fat pad and vehicle (saline) or [10]-gingerol (5 mg/Kg) was administered daily 
intraperitoneally, from day 9 to day 23. Primary tumour growth was measured thrice weekly using electronic callipers. Start and end of 
treatment are indicated with arrows. Difference in growth rate between groups (n = 10 mice/group) was analysed by 2-way ANOVA, 
Bonferroni post-test (*p < 0.05; **p < 0.01). (B) Tumour weight at endpoint (day 26). Data show one point for each mouse (n = 10/group) 
and mean burdens (horizontal bar) ± SD. n/s = not significant, Mann Whitney test (p = 0.109). (C) Detection of active caspase-3 and (D) 
Ki67 in primary tumours. IHC staining of primary tumour sections was carried out as described in Supplementary methods. A total of 
27 images/experimental group (3 images/section x 3 section/tumour 150 µm apart × 3 tumours/group) was analysed. Arrowheads in (D) 
indicate positive Ki67 nuclear reactivity. Data are expressed as mean % of positive pixels/field of view ± SD and the statistical difference 
between groups was analysed using Mann Whitney test; ***p < 0.001. Representative images of control and [10]-gingerol-treated mice 
are shown on the right. Scale bar = 100 µm. (E) Spontaneous lung metastasis. Relative tumour burden (RTB) in lung was quantitated by 
genomic qPCR detection of mCherry gene relative to vimentin as described in Materials and methods. Data show one point for each mouse 
and mean burdens (horizontal bar) ± SD. *p < 0.001, Mann Whitney test. (F) Representative images of lungs from control (saline) and 
[10]-gingerol-treated mice. Arrows indicate metastatic nodules.
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time-point used to assess the impact of [10]-gingerol on 
breast cancer cell proliferation, survival or other cellular 
responses. Since caspase activation is a relatively early 
event, we measured changes in caspase activation in vitro 
after 6 h of treatment with 50 µM [10]-gingerol. Under 
those conditions, caspases-3/9 cleavage was evident 
whereas assays performed with higher [10]-gingerol 
concentrations or longer time-points gave inconsistent 
results (data not shown), most likely due to significant 
loss of cells and more advanced stage of apoptotic death.
Joo and colleagues [18] reported that inhibition 
of lung-metastatic MDA-MB-231 cell proliferation and 
invasion by [10]-gingerol is associated with suppression 
of Akt, p38MAPK and epidermal growth factor receptor. 
Whilst we have tested the impact of [10]-gingerol on long-
term proliferation and migration in brain-metastatic TNBC 
lines, inhibition was observed only at concentrations that 
induce apoptotic death (data not shown) and therefore 
its anti-proliferative/migratory activity could not be 
distinguished from its effect on apoptosis. In addition, 
[10]-gingerol increased caspase-3 activation in tumours 
in vivo but not proliferation, evidenced by expression 
of the Ki67 proliferation marker, further suggesting that 
[10]-gingerol inhibits TNBC growth primarily by inducing 
apoptosis rather than inhibiting cell cycling. Whether 
[10]-gingerol impacts on other cellular responses and 
associated signalling pathways in brain-metastatic TNBC 
cells remains to be determined.
In metastasis assays without primary tumour 
resection, [10]-gingerol concomitantly inhibited orthotopic 
tumour growth and spontaneous lung metastasis. Whilst 
we cannot exclude that inhibition of metastasis was 
partially due to effects on primary tumours in this assay, 
inhibition of lung, bone and brain metastasis observed 
in experimental metastasis assays or when treatment 
commenced after resection of same size tumours 
indicates that [10]-gingerol impacts directly on metastatic 
progression. Importantly, [10]-gingerol was well tolerated, 
improved the overall appearance of mice and prevented 
weight loss due to heavy metastatic burden in bone lung 
and brain seen in control mice. While induction of cell 
death by [10]-gingerol is not rescued by treatment with 
antioxidants [24], it remains possible that blocking of 
reactive oxygen species by [10]-gingerol may contribute 
in part to improved general health of mice in our study 
and to the beneficial effects of ginger extracts in patients 
as suggested by others [25].
A study in healthy human volunteers showed that 
encapsulated ginger extract (up to 2 g of administered 
orally) is well tolerated [26]. However, [10]-gingerol 
half-life was approximately 2h and maximum plasma 
concentration was low (estimated at 0.53 ± 0.4 µg/ml, ~ 
1.5 µM), especially due to its diminished amount in the 
extract. Similarly, Mukkavilli and colleagues [27] recently 
reported that [10]-gingerol is stable and suitable for oral 
administration in mice but that it has poor solubility in 
plasma and rapid clearance in vivo. Together these studies 
suggested that tumour inhibition may not be achievable 
in vivo when [10]-gingerol is administered orally. 
However, these studies differ from ours in many respects. 
In particular, we administered purified [10]-gingerol 
daily by intra-peritoneal injections. It is conceivable 
that [10]-gingerol, while cleared rapidly in plasma, may 
accumulate in tumours upon repeated dosage. This was 
not investigated in the above studies but might explain the 
effects observed in 4T1Br4 tumour-bearing mice.
Our results showed particularly impressive 
inhibition of brain metastasis by [10]-gingerol. This is 
of significance given the syngeneic nature of the 4T1Br4 
model and the important regulatory role of immune cells 
Figure 4: [10]-gingerol inhibits 4T1 experimental metastasis to bone. 4T1Br4 cells (5 × 104) were inoculated into the left 
ventricle of the heart and the mice treated with daily IP injections of vehicle (saline) or [10]-gingerol (10 mg/Kg) as described in Materials 
and methods. Mice were harvested on day 12 and relative tumour burden (RTB) in (A) femur, (B) spine and (C) bone (combined femur 
and spine) determined by genomic qPCR detection of mCherry gene relative to vimentin as described in Supplementary methods. Data 
show one point per mouse (control, n = 10; [10]-gingerol, n = 13) and mean burdens (horizontal bar) ± SD. *p < 0.05; **p < 0.01; ns, not 
significant (spine, p = 0.086, Mann Whitney test).
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Figure 5: [10]-gingerol inhibits 4T1 spontaneous metastasis to brain. 4T1Br4 cells (1 × 105) were inoculated into the mammary 
fat pad and tumours surgically removed when they reached ~0.5 cm3. Mice were treated for 14 days with daily IP injections of vehicle 
(saline) or [10]-gingerol (10 mg/Kg) starting one day after tumour resection and the mice sacrificed on day 14 for quantitation of metastatic 
burden. (A) Primary tumour weight at resection. Each point represents one mouse (Control; n = 14, [10]-gingerol; n = 13). Data were 
analysed for statistical significance using Mann Whitney test. n/s = not significant (p = 0.307). (B) Body weight measurements post-tumour 
resection. *p = 0.041, Mann Whitney test. (C) Incidence of mice with brain metastases. Brains were removed and analysed by fluorescence 
imaging for the presence of mCherry+ve nodules and statistical difference between groups analysed with Fisher’s exact test. *p < 0.05. (D) 
Fluorescence images of brains from each mouse from control (top) and [10]-gingerol-treated (bottom) groups. Note that control brain #14 
in (C) and (D) could not be analysed due to overnight death and cannibalism. Metastatic nodules are indicated by an arrow. Metastatic 
burden in (E) lung, (F) femur, (G) spine and (H) combined bones (femur + spine from same mice) determined by genomic qPCR detection 
of mCherry gene relative to vimentin as described in Supplementary methods. Data are expressed as relative tumour burden (RTB) and 
show one point per mouse (control, n = 14; [10]-gingerol, n = 13) and mean burdens (horizontal bar) ± SD. *p < 0.05; **p < 0.01; ns, not 
significant (spine, p = 0.086, Mann Whitney test).
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in brain metastasis [28]. Surprisingly, despite significantly 
lower incidence of brain metastasis, lesions that developed 
in treated animals showed the presence of a reactive glia 
without appreciable levels of active caspase-3 indicating 
either acquisition of resistance in established lesions and/
or failure to achieve effective therapeutic concentration 
in the brain. Despite their recognised neuro-protective 
properties, the permeability of [10]-gingerol and related 
compounds across the blood-brain barrier and whether 
therapeutic concentration can be achieved in the brain 
remains contentious [21, 29, 30]. The absence of activated 
caspase-3 in established 4T1Br4 brain lesions from treated 
mice suggests that [10]-gingerol may be more effective 
as a ‘preventive’ complementary therapy, targeting 
circulating tumour cells (CTCs) and delaying their homing 
to brain or by inhibiting disseminated tumour cells prior to 
the development of macro-metastases. 
Given the high tolerability and relatively short 
half-life of [10]-gingerol (~2 h) [31], we are currently 
investigating whether greater efficacy against established 
brain metastases could be achieved by increasing the 
dose and/or frequency of treatment. Moreover, in light 
of the relatively low plasma concentrations achieved in 
human or mouse by oral administration (due in part to 
limited absorption and solubility), greater efficacy of 
[10]-gingerol against CTCs or disseminated tumour cells 
could potentially be achieved by improving absorption via 
better oral formulations and/or by strategies to improve the 
bioavailability of free [10]-gingerol in plasma as recently 
proposed [27].
Collectively, our results demonstrated that 
[10]-gingerol inhibits TNBC growth and spontaneous 
metastasis through induction of apoptosis and warrant 
further evaluation of [10]-gingerol in pre-clinical models 
and in patients. In particular, it will be important in 
future experiments to determine whether [10]-gingerol 
treatment in a neo-adjuvant or adjuvant setting could 
extend survival in pre-clinical animal models, either alone 
or in combination with standard systemic therapies. The 
robust and clinically relevant 4T1Br4 brain metastasis 
model gives rise to a high incidence of spontaneous brain 
(and extra-cranial) metastases and will be a valuable tool 
to further evaluate the efficacy and mechanism of action 
of [10]-gingerol or other natural compounds against 
incurable brain metastases.
MATERIALS AND METHODS
Cell culture and reagents
Murine brain-metastatic 4T1Br4 mammary tumour 
cells, derived from parental 4T1 cells (obtained from Dr. 
F. Miller, Karmanos Cancer Institute, Detroit, MI, USA) 
and stably transduced with a pMSCV-mCherry retroviral 
vector [32] were isolated by serial in vivo passaging 
[33]. Briefly, 4T1 cells were inoculated into the 4th 
mammary fat pad and the mice sacrificed after 32 days. 
A rare brain metastasis was isolated, expanded in culture 
and mCherry+ve cells sorted by fluorescence activated 
cell sorting. This procedure was repeated four times to 
generate the 4T1Br4 variant. 4T1Br4 cells and tumours 
lack expression of HER2, oestrogen and progesterone 
receptors and are classified as TNBC [33]. 4T1Br4 and 
4T1BM2 [34] were cultured as described [34] and limited 
to four weeks in culture. MDA-MB-231 and its brain-
metastatic variant, MDA-MB-231BrM, were from Prof 
Joan Massague (Memorial Sloan Kettering Cancer Center, 
NY, USA) and cultured in DMEM, 10% foetal bovine 
serum, sodium pyruvate (1 mM), glutamine (2 mM) and 
1% penicillin-streptomycin. [10]-gingerol was purified as 
described [19]. Stock solutions were prepared in DMSO 
(100 mM) and diluted in saline for in vitro and in vivo 
assays. Controls were treated with the same concentrations 
of DMSO alone and did not exceed 0.1% final.
Determination of [10]-gingerol’s 50% inhibitory 
concentration (IC50)
The cells were seeded in complete medium 
(1 × 103/200 μl/well) in 6 replicate wells of 96-well plates, 
allowed to adhere for 6h and the medium changed to fresh 
medium supplemented with serial dilution of [10]-gingerol 
(200 μl/well, final volume). Cell proliferation was 
measured after 3 days using a sulforhodamine B (SRB) 
colorimetric assay [35]. Briefly, adherent cells were 
fixed by addition of 50 µl of trichloroacetic acid (TCA) 
and stained with a solution of 0.4% SRB dissolved in 
1% acetic acid (100 µl/well). Protein-bound dye was 
released by addition of 100 µl of 10 mM Tris base and 
the absorbance measured by spectrophotometry at 550nm. 
Assays were completed three times and the data presented 
as the mean ± SD of a representative experiment. IC50 
calculations were performed using Hill’s equation in the 
GraphPad Prism 6.0 software.
Colony formation assays
MDA-MB-231BrM and 4T1Br4 cells were plated in 
triplicate in 6 well plates at low density (300 and 100 cells, 
respectively) and incubated overnight at 37°C. Adherent 
cells were treated with [10]-gingerol or vehicle (DMSO) 
for 24 h in 4 ml of serum-containing medium. Colonies 
(> 50 cells) formed after 8 days were fixed with methanol, 
stained with crystal violet and counted. Statistical 
difference between groups was analysed using a 1-way 
ANOVA, Bonferroni post-test; p < 0.05 was considered 
significant.
Cell cycle analysis
Cells (1 × 106) were seeded in 6 cm dishes and 
incubated for 24 h at 37°C, 5% CO2. The cells were 
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treated with 0, 10 or 50 µM of [10]-gingerol and incubated 
for a further 24 h. Cells were detached and pelleted by 
centrifugation, washed with cold PBS, fixed in 70% cold 
ethanol and stored for 24 h at −20°C. Fixed cells were 
incubated with RNase A (0.2 mg/ml) (Sigma, St. Louis, 
MO, USA) at 37°C for 30 min and stained with PI (1 µg/ml) 
(Sigma, St. Louis, MO, USA). DNA content of cells 
(20,000 events) was analysed using an ACCURI C6 flow 
cytometer. Statistical differences between treatments 
for each phase of the cell cycle were analysed by 2-way 
ANOVA and Tukey’s multiple comparison test. p < 0.05 
was considered significant.
Apoptosis assays
The pro-apoptotic activity of [10]-gingerol was 
analysed by flow cytometry with the PE-Annexin-V 
Apoptosis Detection Kit (Becton, Dickinson, Franklin 
Lakes, NJ, USA) or using the TUNEL assay kit (Promega 
Corporation, USA) according to the manufacturer’s 
instructions and as described in Supplementary methods.
Caspase expression
Cells were grown to sub-confluence in triplicate wells 
of a 6-well plate and treated for 6 h with [10]-gingerol (50 
µM) or control vehicle (0.1% DMSO). Whole cell lysates 
were prepared in RIPA buffer (10 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 5 mM EDTA, 1% sodium deoxycholate, 1% 
Triton X-100, 0.1% SDS) and 30 µg proteins loaded onto a 
4–12% gradient SDS-PAGE. Protein bands were transferred 
to a PVDF membrane for 1 h at 100V and the membranes 
blocked for 1 h in PBS, 0.05% Tween-20, 3% normal goat 
serum. The following antibodies were used for detection 
of caspases: caspase-3 (BD Pharmingen, cat# 557035); 
caspase-8 (NOVUS Biologicals, clone FLICE 4-1-20); 
caspase-9 (NOVUS Biologicals, clone LAP6 96-2-22). 
Excess antibodies were washed 3 × 5 min with PBS, 0.05% 
Tween-20, 0.1% BSA and bound antibodies detected with 
appropriate horseradish peroxidase-conjugated secondary 
antibodies. Unbound secondary antibodies were removed 
by washing as above and specific protein bands developed 
using ECL reagents (GE Healthcare Life Sciences).
Metastasis assays
Experimental and spontaneous metastasis assays 
have been described previously [36, 37]. Depending on the 
experimental setting, mice were sacrificed on day 12–28 
as indicated in the figure legends. Tumour growth was 
measured thrice weekly and metastatic burden in lung, 
femur and spine quantitated at endpoint by genomic 
qPCR using Taqman chemistry (Supplementary methods) 
[36, 37]. For experiments requiring primary tumour 
excision, mice were anesthetised by IP administration of 
ketamine (40 µg/g)/xylazil (16 µg/ml) and primary tumours 
surgically removed when they reached approximately 
0.5 cm3 (~0.5 g) and weighed. Brains were removed, 
imaged on an IVIS Spectrum and processed for paraffin-
embedding and IHC staining (Supplementary methods).
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